CD133 Expression in the Nucleus Is Associated with Endometrial Carcinoma Staging and Tumor Angioinvasion
Abstract
:1. Introduction
2. Materials and Methods
2.1. Patients and Ethics Approval
2.2. Immunohistochemical Analysis of CD133 Expression
2.3. Bioinformatical and Statistical Analysis of the Data
3. Results
3.1. CD133 Is Positively Expressed in the Nucleus, Whereas Its Expression in the Plasma Membrane Is Negatively Associated with Higher Grade and Stage of Endometrial Cancer
3.2. CD133 Expression in the Nucleus Is Positively Associated with Higher FIGO Stages IB-IV in Comparison to FIGO IA
3.3. CD133 Expression in the Nucleus and Plasma Membrane Is Positively and Negatively Associated with Tumor Angioinvasion, Respectively
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Glumac, P.M.; LeBeau, A.M. The role of CD133 in cancer: A concise review. Clin. Transl. Med. 2018, 7, 18. [Google Scholar] [CrossRef] [PubMed]
- Corbeil, D.; Roandper, K.; Fargeas, C.A.; Joester, A.; Huttner, W.B. Prominin: A story of cholesterol, plasma membrane protrusions and human pathology. Traffic 2001, 2, 82–91. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Röper, K.; Corbeil, D.; Huttner, W.B. Retention of prominin in microvilli reveals distinct cholesterol-based lipid microdomains in the apical plasma membrane. Nat. Cell Biol. 2000, 2, 582–592. [Google Scholar] [CrossRef] [PubMed]
- Grosse-Gehling, P.; Fargeas, C.A.; Dittfeld, C.; Garbe, Y.; Alison, M.R.; Corbeil, D.; Kunz-Schughart, L.A. CD133 as a biomarker for putative cancer stem cells in solid tumours: Limitations, problems and challenges. J. Pathol. 2013, 229, 355–378. [Google Scholar] [CrossRef]
- Giannone, G.; Attademo, L.; Scotto, G.; Genta, S.; Ghisoni, E.; Tuninetti, V.; Aglietta, M.; Pignata, S.; Valabrega, G. Endometrial cancer stem cells: Role, characterization and therapeutic implications. Cancers 2019, 11, 1820. [Google Scholar] [CrossRef] [Green Version]
- Yu, G.-F.; Lin, X.; Luo, R.-C.; Fang, W.-Y. Nuclear CD133 expression predicts poor prognosis for hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 2018, 11, 2092–2099. [Google Scholar]
- Lee, Y.M.; Yeo, M.K.; Seong, I.O.; Kim, K.H. Nuclear expression of CD133 is associated with good prognosis in patients with colorectal adenocarcinoma. Anticancer Res. 2018, 38, 4819–4826. [Google Scholar] [CrossRef]
- Turano, M.; Costabile, V.; Cerasuolo, A.; Duraturo, F.; Liccardo, R.; Delrio, P.; Pace, U.; Rega, D.; Dodaro, C.A.; Milone, M.; et al. Characterisation of mesenchymal colon tumour-derived cells in tumourspheres as a model for colorectal cancer progression. Int. J. Oncol. 2018, 53, 2379–2396. [Google Scholar] [CrossRef] [Green Version]
- Cantile, M.; Collina, F.; D’Aiuto, M.; Rinaldo, M.; Pirozzi, G.; Borsellino, C.; Franco, R.; Botti, G.; Di Bonito, M. Nuclear localization of cancer stem cell marker CD133 in triple-negative breast cancer: A case report. Tumori 2013, 99, e245–e250. [Google Scholar] [CrossRef]
- Huang, M.; Zhu, H.; Feng, J.; Ni, S.; Huang, J. High CD133 Expression in the Nucleus and Cytoplasm Predicts Poor Prognosis in Non-Small Cell Lung Cancer. Dis. Markers 2015. [Google Scholar] [CrossRef]
- Chen, Y.L.; Lin, P.Y.; Ming, Y.Z.; Huang, W.C.; Chen, R.F.; Chen, P.M.; Chu, P.Y. The effects of the location of cancer stem cell marker CD133 on the prognosis of hepatocellular carcinoma patients. BMC Cancer 2017, 17, 474. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mleko, M.; Pietrus, M.; Duda-Wiewióra, M.; Pitynski, K. CD133 cells in endometrial cancer. Curr. Gynecol. Oncol. 2019, 17, 173–177. [Google Scholar] [CrossRef]
- Chan, J.K.; Sherman, A.E.; Kapp, D.S.; Zhang, R.; Osann, K.E.; Maxwell, L.; Chen, L.-M.; Deshmukh, H. Influence of gynecologic oncologists on the survival of patients with endometrial cancer. J. Clin. Oncol. 2011, 29, 832–838. [Google Scholar] [CrossRef]
- Scholten, A.N.; Smit, V.T.H.B.M.; Beerman, H.; van Putten, W.L.J.; Creutzberg, C.L. Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 2004, 100, 764–772. [Google Scholar] [CrossRef] [PubMed]
- Amant, F.; Mirza, M.R.; Koskas, M.; Creutzberg, C.L. Cancer of the corpus uteri. Int. J. Gynecol. Obstet. 2018, 143, 37–50. [Google Scholar] [CrossRef] [Green Version]
- Pitynski, K.; Banas, T.; Pietrus, M.; Milian-Ciesielska, K.; Ludwin, A.; Okon, K. SOX-2, but not Oct 4, is highly expressed in early-stage endometrial adenocarcinoma and is related to tumour grading. Int. J. Clin. Exp. Pathol. 2015, 8, 8189–8198. [Google Scholar]
- Friel, A.M.; Zhang, L.; Curley, M.D.; Therrien, V.A.; Sergent, P.A.; Belden, S.E.; Borger, D.R.; Mohapatra, G.; Zukerberg, L.R.; Foster, R.; et al. Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod. Biol. Endocrinol. 2010, 8, 147. [Google Scholar] [CrossRef] [Green Version]
- Lee, P.; Li, X. Expression Profiles of the Phosphatase and Tensin Homolog (PTEN), CDH1, and CDH2 Genes, and the Cell Membrane Protein, CD133, in the Ishikawa Human Endometrial Adenocarcinoma Cell Line. Med. Sci. Monit. 2019, 25, 9829–9835. [Google Scholar] [CrossRef] [PubMed]
- Sun, Y.; Yoshida, T.; Okabe, M.; Zhou, K.; Wang, F.; Soko, C.; Saito, S.; Nikaido, T. Isolation of Stem-Like Cancer Cells in Primary Endometrial Cancer Using Cell Surface Markers CD133 and CXCR4. Transl. Oncol. 2017, 10, 976–987. [Google Scholar] [CrossRef] [Green Version]
- Mancebo, G.; Sole-Sedeno, J.M.; Pino, O.; Miralpeix, E.; Mojal, S.; Garrigos, L.; Lloveras, B.; Navarro, P.; Gibert, J.; Lorenzo, M.; et al. Prognostic impact of CD133 expression in Endometrial Cancer Patients. Sci. Rep. 2017, 7, 7687. [Google Scholar] [CrossRef]
- Ding, D.C.; Liu, H.W.; Chang, Y.H.; Chu, T.Y. Expression of CD133 in endometrial cancer cells and its implications. J. Cancer 2017, 8, 2142–2153. [Google Scholar] [CrossRef] [Green Version]
- Nakamura, M.; Kyo, S.; Zhang, B.; Zhang, X.; Mizumoto, Y.; Takakura, M.; Maida, Y.; Mori, N.; Hashimoto, M.; Ohno, S.; et al. Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum. Pathol. 2010, 41, 1516–1529. [Google Scholar] [CrossRef]
- Rutella, S.; Bonanno, G.; Procoli, A.; Mariotti, A.; Corallo, M.; Prisco, M.G.; Eramo, A.; Napoletano, C.; Gallo, D.; Perillo, A.; et al. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin. Cancer Res. 2009, 15, 4299–4311. [Google Scholar] [CrossRef] [Green Version]
- Chen, G.; Liu, B.; Yin, S.; Li, S.; Guo, Y.; Wang, M.; Wang, K.; Wan, X. Hypoxia induces an endometrial cancer stem-like cell phenotype via HIF-dependent demethylation of SOX2 mRNA. Oncogenesis 2020, 9, 81. [Google Scholar] [CrossRef] [PubMed]
- Gao, Y.; Liu, T.; Cheng, W.; Wang, H. Isolation and characterization of proliferative, migratory and multidrug-resistant endometrial carcinoma-initiating cells from human type II endometrial carcinoma cell lines. Oncol. Rep. 2012, 28, 527–532. [Google Scholar] [CrossRef] [PubMed]
- Elbasateeny, S.S.; Salem, A.A.; Abdelsalam, W.A.; Salem, R.A. Immunohistochemical expression of cancer stem cell related markers CD44 and CD133 in endometrial cancer. Pathol. Res. Pract. 2016, 212, 10–16. [Google Scholar] [CrossRef] [PubMed]
- Creasman, W.T.; Odicino, N.; Maisonneuve, P.; Quinn, M.A.; Beller, U.; Benedet, J.L.; Heintz, A.P.M.; Ngan, H.Y.S.; Pecorelli, S. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int. J. Gynaecol. Obstet. 2006, 95 (Suppl. 1), S105–S143. [Google Scholar] [CrossRef]
- Singer, D.; Thamm, K.; Zhuang, H.; Karbanová, J.; Gao, Y.; Walker, J.V.; Jin, H.; Wu, X.; Coveney, C.R.; Marangoni, P.; et al. Prominin-1 controls stem cell activation by orchestrating ciliary dynamics. EMBO J. 2019, 38, e99845. [Google Scholar] [CrossRef]
- Chen, C.L.; Hsieh, F.C.; Lieblein, J.C.; Brown, J.; Chan, C.; Wallace, J.A.; Cheng, G.; Hall, B.M.; Lin, J. Stat3 activation in human endometrial and cervical cancers. Br. J. Cancer 2007, 96, 591–599. [Google Scholar] [CrossRef]
- Feng, Y.Z.; Shiozawa, T.; Miyamoto, T.; Kashima, H.; Kurai, M.; Suzuki, A.; Ying-Song, J.; Konishi, I. Overexpression of hedgehog signaling molecules and its involvement in the proliferation of endometrial carcinoma cells. Clin. Cancer Res. 2007, 13, 1389–1398. [Google Scholar] [CrossRef] [Green Version]
- Polychronidou, G.; Kotoula, V.; Manousou, K.; Kostopoulos, I.; Karayannopoulou, G.; Vrettou, E.; Bobos, M.; Raptou, G.; Efstratiou, I.; Dionysopoulos, D.; et al. Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer. PLoS ONE 2018, 13, e0208221. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Collet, G.; Skrzypek, K.; Grillon, C.; Matejuk, A.; El Hafni-Rahbi, B.; Lamerant-Fayel, N.; Kieda, C. Hypoxia control to normalize pathologic angiogenesis: Potential role for endothelial precursor cells and miRNAs regulation. Vascul. Pharmacol. 2012, 56, 1–10. [Google Scholar] [CrossRef]
- Concin, N.; Matias-Guiu, X.; Vergote, I.; Cibula, D.; Mirza, M.R.; Marnitz, S.; Ledermann, J.; Bosse, T.; Chargari, C.; Fagotti, A.; et al. ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int. J. Gynecol. Cancer 2021, 31, 12–39. [Google Scholar] [CrossRef]
- Corte, L.D.; Giampaolino, P.; Mercorio, A.; Riemma, G.; Schiattarella, A.; de Franciscis, P.; Bifulco, G. Sentinel lymph node biopsy in endometrial cancer: State of the art. Transl. Cancer Res. 2020, 9, 7725–7733. [Google Scholar] [CrossRef]
- Ferrari, F.; Forte, S.; Arrigoni, G.; Ardighieri, L.; Coppola, M.C.; Salinaro, F.; Barra, F.; Sartori, E.; Odicino, F. Impact of endometrial sampling technique and biopsy volume on the diagnostic accuracy of endometrial cancer. Transl. Cancer Res. 2020, 9, 7697–7705. [Google Scholar] [CrossRef]
Number of Patients | 64 |
---|---|
Age | 61.2 ± 11.3 |
Age of the first menstruation | 13.8 ± 1.5 |
Length of women’s monthly cycle (days) | 28.7 ± 3.4 |
Length of menstruation (days) | 5.5 ± 3.3 |
Age of the last menstruation | 50.7 ± 4.3 |
Number of pregnancies | |
0 | 4 (6.3%) |
1 | 13 (20.3%) |
2 | 27 (42.2%) |
3 | 14(21.9%) |
4 | 4 (6.3%) |
5 | 0 |
6 | 1 (1.6%) |
Lack of data | 1 (1.6%) |
FIGO | |
I | 43 (67.2%) |
II | 12 (18.8%) |
III | 8 (12.5%) |
IV | 1 (1.6%) |
Grading | |
1 | 17 (26.6%) |
2 | 23 (35.95%) |
3 | 24 (37.5%) |
Grade 1 (n = 17) | Grade 2 (n = 23) | Grade 3 (n = 24) | p-Value | |
---|---|---|---|---|
CD133 in cytoplasm (% of cells) | 85 ± 16.1 | 80.4 ± 16.2 | 83.5 ± 10.6 | 0.61 |
CD133 in nucleus (% of cells) | 27.9 ± 31.3 | 47 ± 30 | 75.7 ± 23.8 * † | <0.0001 |
CD133 in plasma membrane (% of cells) | 48.8 ± 25 | 36.4 ± 29.5 | 16.1 ± 22.3 ** ‡ | 0.005 |
FIGO | ||||
I | 15 (88.2%) | 18 (78.3%) | 10 (41.7%) | |
II | 1(5.9%) | 4 (17.4%) | 7 (29.2%) | |
III | 1 (5.9%) | 1 (4.4%) | 6 (25%) | 0.04 |
IV | 0 | 0 | 1 (4.2%) |
FIGO IA (n = 23) | FIGO IB-IV (n = 41) | p-Value | |
---|---|---|---|
CD133 in cytoplasm (% of cells) | 82.6 ± 12.5 | 82.3 ± 15.2 | 0.94 |
CD133 in nucleus (% of cells) | 37.4 ± 30.8 | 61.2 ± 32.9 | 0.006 |
CD133 in plasma membrane (% of cells) | 38.6 ± 29.1 | 28.5 ± 28.2 | 0.18 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pietrus, M.; Pitynski, K.; Waligora, M.; Milian-Ciesielska, K.; Bialon, M.; Ludwin, A.; Skrzypek, K. CD133 Expression in the Nucleus Is Associated with Endometrial Carcinoma Staging and Tumor Angioinvasion. J. Clin. Med. 2021, 10, 2144. https://doi.org/10.3390/jcm10102144
Pietrus M, Pitynski K, Waligora M, Milian-Ciesielska K, Bialon M, Ludwin A, Skrzypek K. CD133 Expression in the Nucleus Is Associated with Endometrial Carcinoma Staging and Tumor Angioinvasion. Journal of Clinical Medicine. 2021; 10(10):2144. https://doi.org/10.3390/jcm10102144
Chicago/Turabian StylePietrus, Milosz, Kazimierz Pitynski, Marcin Waligora, Katarzyna Milian-Ciesielska, Monika Bialon, Artur Ludwin, and Klaudia Skrzypek. 2021. "CD133 Expression in the Nucleus Is Associated with Endometrial Carcinoma Staging and Tumor Angioinvasion" Journal of Clinical Medicine 10, no. 10: 2144. https://doi.org/10.3390/jcm10102144